These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 26871284)

  • 1. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer.
    Dai C; Lin F; Geng R; Ge X; Tang W; Chang J; Wu Z; Liu X; Lin Y; Zhang Z; Li J
    Oncotarget; 2016 Mar; 7(9):10332-44. PubMed ID: 26871284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.
    Wu X; Sharma A; Oldenburg J; Weiher H; Essler M; Skowasch D; Schmidt-Wolf IGH
    Front Immunol; 2021; 12():731767. PubMed ID: 34691037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
    Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
    Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
    Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
    Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
    Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines.
    Durrieu L; Lemieux W; Dieng MM; Fontaine F; Duval M; Le Deist F; Haddad E
    Cytotherapy; 2014 Jun; 16(6):845-56. PubMed ID: 24529554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
    Lote H; Cafferkey C; Chau I
    Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy using NKG2D and DNAM-1 systems.
    Morisaki T; Onishi H; Katano M
    Anticancer Res; 2012 Jun; 32(6):2241-7. PubMed ID: 22641658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.
    Cheng M; Ma J; Chen Y; Zhang J; Zhao W; Zhang J; Wei H; Ling B; Sun R; Tian Z
    Cell Transplant; 2011; 20(11-12):1731-46. PubMed ID: 21669033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the dual-functional capability of CIK cells be used to improve antitumor effects?
    Wang X; Yu W; Li H; Yu J; Zhang X; Ren X; Cao S
    Cell Immunol; 2014 Jan; 287(1):18-22. PubMed ID: 24355711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition.
    Wei F; Rong XX; Xie RY; Jia LT; Wang HY; Qin YJ; Chen L; Shen HF; Lin XL; Yang J; Yang S; Hao WC; Chen Y; Xiao SJ; Zhou HR; Lin TY; Chen YS; Sun Y; Yao KT; Xiao D
    Oncotarget; 2015 Oct; 6(33):35023-39. PubMed ID: 26418951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers.
    Liu Y; Cheng Y; Xu Y; Wang Z; Du X; Li C; Peng J; Gao L; Liang X; Ma C
    Oncogene; 2017 Nov; 36(44):6143-6153. PubMed ID: 28692048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells.
    Su X; Zhang L; Jin L; Ye J; Guan Z; Chen R
    J Clin Immunol; 2010 Sep; 30(5):766-74. PubMed ID: 20549316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression.
    Giuliani M; Janji B; Berchem G
    Oncotarget; 2017 Apr; 8(14):24031-24044. PubMed ID: 28199990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy.
    Li J; Chen L; Xiong Y; Zheng X; Xie Q; Zhou Q; Shi L; Wu C; Jiang J; Wang H
    Cell Physiol Biochem; 2017; 41(3):907-920. PubMed ID: 28222426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
    Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
    Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.